Skip to content

Study of warm poultice in the management of Osteoarthritis knee.

Evaluation of the effect of Upanaha treatment with Vachadi Upanaha Churna in Osteoarthritis (OA Knee) wrt pain and stiffness of joints - Upanaha

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/01/007691
Enrollment
60
Registered
2017-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- suffering from Osteoarthritis knee

Interventions

Intervention1: Upanaha: Upanaha (warm poultice) with Vachadi Upanaha churna once a day for 14 days Control Intervention1: Nil: Nil

Sponsors

Central Council For Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged between 35 and 65 years. 2. Subjects having VAS score for knee pain between 45-74 mm (moderate pain) 3. Clinical and radiological evidence of Osteoarthritis knee (Unilateral/ bilateral) as per ACR criteria (i) knee pain, (ii) at least one of three (a) Age > 50 years (b) stiffness (c) Crepitus (iii) Osteophytes 4. Radiographical changes as per Grade I to III of Kellgren& Lawrence Radiological scale 5. Able and willing to participate and provide signed informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with Grade IV Kellgren& Lawrence Radiological scale 2. History of any trauma/ fractured joint / surgical/diagnostic intervention with reference to the affected joint(s). 3. H/O monoarthritis/ polyarthritis other than Osteoarthritis Knee such as gouty arthritis, rheumatoid arthritis and psoriatic arthritis etc. 4. Any unstable cardio-vascular disease. 5. Patients with uncontrolled Hypertension ( >160/100 mmHg) 6. Patients with uncontrolled Diabetes Mellitus having HbA1C >7.5% 7. Patients with evidence of malignancy. 8. Patients with any concurrent hepatic disorder (defined as liver enzymes SGOT/SGPT >2 times upper normal limit) or Renal Disorders (defined as S.Creatinine >1.4mg/dl) or Pulmonary Dysfunction 9. The patient has been administered any chondroprotective drugs, intra-articular injection into the affected joint or systemic medication with corticosteroids during the preceding 3 months. 10. Pregnant / lactating woman. 11. Patients who are currently participating in any other clinical trial. 12. Any other condition which the Principal Investigator thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
â?¢ Change in the visual analogue scale (VAS) for pain in last 48 hrs â?¢ Change in the visual analogue scale (VAS) for stiffness in last 48 hrs â?¢ Change in WOMAC total score â?¢ Change in WOMAC subscales (pain, function and stiffness) Timepoint: â?¢ Change in the visual analogue scale (VAS) for pain in last 48 hrs from baseline to 14th day â?¢ Change in the visual analogue scale (VAS) for stiffness in last 48 hrs from baseline to 14th day â?¢ Change in WOMAC total score from baseline to 14 th day â?¢ Change in WOMAC subscales (pain, function and stiffness) from baseline to 14 th day

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Deepa Makhija

Central Ayurveda Research Institute for Cardio-vascular Diseases

drdeepamakhija@yahoo.co.in01125225546

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026